Newron completes screening for ENIGMA-TRS 1 Phase 3 enrollment
Newron Pharmaceuticals said it has completed screening for enrollment in its pivotal Phase 3 ENIGMA-TRS 1 study. Evenamide will be used as add-on therapy in patients with treatment-resistant schizophrenia.
Newron Pharmaceuticals S.p.A./ Key word(s): StudyNewron announces completion of screening for enrollment in pivotal Phase 3 ENIGMA-TRS 1 study with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)02.09.2026 / 07:00 CET/CESTThe issuer is solely responsible for the…